Will Cosmeceutical Pioneer Turn Its Wagons Around? FDA Warns Strivectin

FDA cites Strivectin’s Potent Wrinkle Reducing Treatment and TL Advanced Tightening Neck Cream as unapproved drugs based on claims touting elastin-stimulating effects, skin-firming action and other structure/function benefits. Widely credited as a pioneer that helped create the cosmeceutical category, Strivectin has been warning-free since 2005 when FDA came down on its “Better than Botox?” positioning.

Strivectin blazed an early trail in the cosmeceutical frontier with its results-driven skin-care platform, but claims for at least two of its offerings identify the products as unapproved drugs, according to an FDA warning letter.

Posted to FDA’s website March 9, the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from HBW Insight

Unilever Anti-Dandruff Range Responds To ‘Explosive’ Category Growth In China

 

British company Unilever PLC expands its Clear anti-dandruff collection with a five-product range that targets scalp concerns including oiliness, dandruff and sensitivity.

People On The Move: Appointments At Haleon, Wellnex, Orkla

 
• By 

A round-up of the latest consumer health leadership changes: Haleon names Middle East & Africa unit manager; Wellnex Life appoints interim chair; Orkla Health appoints CEO.

Over The Counter: Everything You Wanted To Know About Real World Evidence, With IQVIA’s Volker Spitzer

 
• By 

HBW Insight finds out all about real world evidence and its potential for the OTC industry by chatting with IQVIA Consumer Health's vice president of global research and development and real-world evidence services, Volker Spitzer.